Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2008

01.09.2008 | Gastrointestinal Oncology

Liver Surgery for Colorectal Metastases: Results after 10 Years of Follow-Up. Long-Term Survivors, Late Recurrences, and Prognostic Role of Morbidity

verfasst von: Luca Viganò, MD, Alessandro Ferrero, MD, Roberto Lo Tesoriere, MD, Lorenzo Capussotti, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Liver surgery is the gold-standard treatment of colorectal liver metastases. Five-year survival rates may be inadequate to evaluate surgical outcomes because some patients are alive with recurrence and late recurrences are possible. The aim of this study was to analyze 10-year survival outcome in terms of late recurrence rate and prognostic factors of survival.

Methods

One hundred twenty-five patients underwent liver resection for colorectal liver metastases between 1985 and 1996. Four patients who experienced postoperative mortality were excluded. The analysis was performed on 121 patients.

Results

Five- and 10-year survival rates were 23.1% and 15.7%, respectively. Nineteen patients were alive 10 years after liver resection and 17 were disease-free (5 after re-resection). Five- and 10-year disease-free survival rates were 17.4% and 14.8%, respectively. In patients with recurrence, re-resection significantly improved survival (P < 0.001); 98% of recurrences occurred within the first 5 years, but 15% of patients disease-free at 5 years developed later recurrence. Multivariate analysis evidenced five independent negative prognostic factors of survival: male sex (P = 0.029), synchronous metastases (P = 0.011), >3 metastases (P < 0.001), metastatic infiltration of nearby structures (P < 0.001), and postoperative morbidity (P < 0.001). In 17 patients without negative prognostic factors the 10-year survival rate was 35.3%.

Conclusion

Liver resection for colorectal liver metastases may be curative in more than one-third of patients without negative prognostic factors. Postoperative morbidity significantly worsens long-term outcomes. The risk of recurrence after liver resection is high even after 5 years of follow-up, but re-resection can improve the outcome.
Literatur
1.
Zurück zum Zitat Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007; 11:1057–77PubMedCrossRef Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007; 11:1057–77PubMedCrossRef
2.
Zurück zum Zitat Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006; 94:982–99PubMedCrossRef Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006; 94:982–99PubMedCrossRef
3.
Zurück zum Zitat Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984; 199:502–8PubMedCrossRef Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984; 199:502–8PubMedCrossRef
4.
Zurück zum Zitat Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990; 77:1241–6PubMedCrossRef Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990; 77:1241–6PubMedCrossRef
5.
Zurück zum Zitat Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 2000; 231:487–99PubMedCrossRef Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 2000; 231:487–99PubMedCrossRef
6.
Zurück zum Zitat D’Angelica M, Brennan MF, Fortner JG, et al. Ninety-six five-year survivors after liver resection for metastatic colorectal cancer. J Am Coll Surg 1997; 185:554–9PubMedCrossRef D’Angelica M, Brennan MF, Fortner JG, et al. Ninety-six five-year survivors after liver resection for metastatic colorectal cancer. J Am Coll Surg 1997; 185:554–9PubMedCrossRef
7.
Zurück zum Zitat Tanaka K, Shimada H, Ueda M, et al. Long-term characteristics of 5-year survivors after liver resection for colorectal metastases. Ann Surg Oncol 2007; 14:1336–46PubMedCrossRef Tanaka K, Shimada H, Ueda M, et al. Long-term characteristics of 5-year survivors after liver resection for colorectal metastases. Ann Surg Oncol 2007; 14:1336–46PubMedCrossRef
8.
Zurück zum Zitat Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Analysis of 1001 consecutive cases. Ann Surg 1999; 230:309–21PubMedCrossRef Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Analysis of 1001 consecutive cases. Ann Surg 1999; 230:309–21PubMedCrossRef
9.
Zurück zum Zitat Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240:644–57PubMedCrossRef Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240:644–57PubMedCrossRef
10.
Zurück zum Zitat Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25:4575–80PubMedCrossRef Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25:4575–80PubMedCrossRef
11.
Zurück zum Zitat Capussotti L, Muratore A, Mulas MM, et al. Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg 2006; 93:1001–6PubMedCrossRef Capussotti L, Muratore A, Mulas MM, et al. Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg 2006; 93:1001–6PubMedCrossRef
12.
Zurück zum Zitat Elias D, Debaere T, Muttillo I, et al. Intraoperative use of radiofrequency treatment allows an increase in the rate of curative liver resection. J Surg Oncol 1998; 67:190–1PubMedCrossRef Elias D, Debaere T, Muttillo I, et al. Intraoperative use of radiofrequency treatment allows an increase in the rate of curative liver resection. J Surg Oncol 1998; 67:190–1PubMedCrossRef
13.
Zurück zum Zitat Pawlik TM, Izzo F, Cohen DS, et al. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003; 10:1059–69PubMedCrossRef Pawlik TM, Izzo F, Cohen DS, et al. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003; 10:1059–69PubMedCrossRef
14.
Zurück zum Zitat Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241:715–22PubMedCrossRef Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241:715–22PubMedCrossRef
15.
Zurück zum Zitat Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240:438–47PubMedCrossRef Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240:438–47PubMedCrossRef
16.
Zurück zum Zitat Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg 2007; 246:183–91PubMedCrossRef Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg 2007; 246:183–91PubMedCrossRef
17.
Zurück zum Zitat Muratore A, Polastri R, Bouzari H, et al. Repeat hepatectomy for colorectal liver metastases: a worthwhile operation? J Surg Oncol 2001; 76:127–32PubMedCrossRef Muratore A, Polastri R, Bouzari H, et al. Repeat hepatectomy for colorectal liver metastases: a worthwhile operation? J Surg Oncol 2001; 76:127–32PubMedCrossRef
18.
Zurück zum Zitat Adam R, Bismuth H, Castaing D, et al. Repeat hepatectomy for colorectal metastases. Ann Surg 1997; 225:51–62PubMedCrossRef Adam R, Bismuth H, Castaing D, et al. Repeat hepatectomy for colorectal metastases. Ann Surg 1997; 225:51–62PubMedCrossRef
19.
Zurück zum Zitat Fernandez-Trigo V, Shamsa F, Sugarbaker PH, et al. Repeat liver resections from colorectal metastasis. Surgery 1995; 117:296–304PubMedCrossRef Fernandez-Trigo V, Shamsa F, Sugarbaker PH, et al. Repeat liver resections from colorectal metastasis. Surgery 1995; 117:296–304PubMedCrossRef
20.
Zurück zum Zitat Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002; 235:863–71PubMedCrossRef Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002; 235:863–71PubMedCrossRef
21.
Zurück zum Zitat Adam R, Pascal G, Azoulay D, et al. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 2003; 238:871–83PubMedCrossRef Adam R, Pascal G, Azoulay D, et al. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 2003; 238:871–83PubMedCrossRef
22.
Zurück zum Zitat Imamura H, Kawasaki S, Miyagawa S, et al. Aggressive surgical approach to recurrent tumors after hepatectomy for metastatic spread of colorectal cancer to the liver. Surgery 2000; 127:528–35PubMedCrossRef Imamura H, Kawasaki S, Miyagawa S, et al. Aggressive surgical approach to recurrent tumors after hepatectomy for metastatic spread of colorectal cancer to the liver. Surgery 2000; 127:528–35PubMedCrossRef
23.
Zurück zum Zitat Miller G, Biernacki P, Kemeny NE, et al. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 2007; 205:231–8PubMedCrossRef Miller G, Biernacki P, Kemeny NE, et al. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 2007; 205:231–8PubMedCrossRef
24.
Zurück zum Zitat Yedibela S, Klein P, Feuchter K, et al. Surgical management of pulmonary metastases from colorectal cancer in 153 patients. Ann Surg Oncol 2006; 13:1538–44PubMedCrossRef Yedibela S, Klein P, Feuchter K, et al. Surgical management of pulmonary metastases from colorectal cancer in 153 patients. Ann Surg Oncol 2006; 13:1538–44PubMedCrossRef
25.
Zurück zum Zitat Elias D, Sideris L, Pocard M, et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004; 11:274–80PubMedCrossRef Elias D, Sideris L, Pocard M, et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004; 11:274–80PubMedCrossRef
26.
Zurück zum Zitat Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003; 90:963–9PubMedCrossRef Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003; 90:963–9PubMedCrossRef
27.
Zurück zum Zitat Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996; 77:1254–62PubMedCrossRef Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996; 77:1254–62PubMedCrossRef
28.
Zurück zum Zitat Ekberg H, Tranberg KG, Andersson R, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986; 73:727–31PubMedCrossRef Ekberg H, Tranberg KG, Andersson R, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986; 73:727–31PubMedCrossRef
29.
Zurück zum Zitat Stephenson KR, Steinberg SM, Hughes KS, et al. Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg 1988; 208:679–87PubMedCrossRef Stephenson KR, Steinberg SM, Hughes KS, et al. Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg 1988; 208:679–87PubMedCrossRef
30.
Zurück zum Zitat Capussotti L, Viganò L, Ferrero A, et al. Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model. Ann Surg Oncol 2007; 14:1143–50PubMedCrossRef Capussotti L, Viganò L, Ferrero A, et al. Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model. Ann Surg Oncol 2007; 14:1143–50PubMedCrossRef
31.
Zurück zum Zitat Moroz P, Salama PR, Gray BN. Resecting large numbers of hepatic colorectal metastases. ANZ J Surg 2002; 72:5–10PubMedCrossRef Moroz P, Salama PR, Gray BN. Resecting large numbers of hepatic colorectal metastases. ANZ J Surg 2002; 72:5–10PubMedCrossRef
32.
Zurück zum Zitat Hirai T, Yamashita Y, Mukaida H, et al. Poor prognosis in esophageal cancer patients with postoperative complications. Surg Today 1998; 28:576–9PubMedCrossRef Hirai T, Yamashita Y, Mukaida H, et al. Poor prognosis in esophageal cancer patients with postoperative complications. Surg Today 1998; 28:576–9PubMedCrossRef
33.
Zurück zum Zitat Fujita S, Teramoto T, Watanabe M, et al. Anastomotic leakage after colorectal cancer surgery: a risk factor for recurrence and poor prognosis. Jpn J Clin Oncol 1993; 23:299–302PubMed Fujita S, Teramoto T, Watanabe M, et al. Anastomotic leakage after colorectal cancer surgery: a risk factor for recurrence and poor prognosis. Jpn J Clin Oncol 1993; 23:299–302PubMed
34.
Zurück zum Zitat de Melo GM, Ribeiro KC, Kowalski LP, et al. Risk factors for postoperative complications in oral cancer and their prognostic implications. Arch Otolaryngol Head Neck Surg 2001; 127:828–33PubMed de Melo GM, Ribeiro KC, Kowalski LP, et al. Risk factors for postoperative complications in oral cancer and their prognostic implications. Arch Otolaryngol Head Neck Surg 2001; 127:828–33PubMed
35.
Zurück zum Zitat Mynster T, Christensen IJ, Moesgaard F, et al. Effects of the combination of blood transfusion and postoperative infectious complications on prognosis after surgery for colorectal cancer. Danish RANX05 Colorectal Cancer Study Group. Br J Surg 2000; 87:1553–62PubMedCrossRef Mynster T, Christensen IJ, Moesgaard F, et al. Effects of the combination of blood transfusion and postoperative infectious complications on prognosis after surgery for colorectal cancer. Danish RANX05 Colorectal Cancer Study Group. Br J Surg 2000; 87:1553–62PubMedCrossRef
36.
Zurück zum Zitat Panis Y, Ribeiro J, Chrétien Y, et al. Dormant liver metastases: an experimental study. Br J Surg 1992; 79:221–3PubMedCrossRef Panis Y, Ribeiro J, Chrétien Y, et al. Dormant liver metastases: an experimental study. Br J Surg 1992; 79:221–3PubMedCrossRef
37.
Zurück zum Zitat Laurent C, Sa Cunha A, Couderc P, et al. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg 2003; 90:1131–6PubMedCrossRef Laurent C, Sa Cunha A, Couderc P, et al. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg 2003; 90:1131–6PubMedCrossRef
Metadaten
Titel
Liver Surgery for Colorectal Metastases: Results after 10 Years of Follow-Up. Long-Term Survivors, Late Recurrences, and Prognostic Role of Morbidity
verfasst von
Luca Viganò, MD
Alessandro Ferrero, MD
Roberto Lo Tesoriere, MD
Lorenzo Capussotti, MD
Publikationsdatum
01.09.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-9935-9

Weitere Artikel der Ausgabe 9/2008

Annals of Surgical Oncology 9/2008 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.